CD38 and AL amyloidosis: Targeting CD38 with the monoclonal antibody daratumumab (Dara) is a widely used treatment in the setting of relapsed or refractory multiple myeloma (MM).1, 2, 3, 4, 5, 6 Therefore, Dara is currently approved, in combination with lenalidomide or bortezomib, for treatment of patients with MM who have received at least one prior line of treatment.